

DOCTORAL THESIS

Study of the anti-cancer effect and mechanism of compound 9: a novel derivative of the PPD-type ginsenoside

Dong, Hang

Date of Award:
2012

[Link to publication](#)

General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

**Study of The Anti-cancer Effect and Mechanism of Compound 9,
a Novel Derivative of the PPD-type Ginsenoside**

DONG Hang

A thesis submitted in partial fulfillment of the requirements

for the degree of

Doctor of Philosophy

Principal Supervisor: Dr. Yu Zhiling

Hong Kong Baptist University

March 2012

ABSTRACT

In the research of drug discovery it shows promise from natural sources. However, the ideal therapeutics for cancer treatment remains still in highly demanding. In the past decades, much attention has been paid on screening ideal anti-cancer agents from ginseng radix et rhizoma (ginseng) as it has been popularly used as a healthful medicinal herb in Asian countries for prevention and treatment of various illnesses including cancers. Previous reports showed the extracts of ginseng to be effective of inhibiting cancers in humans and animals. Also, the total ginsenosides and a number of purified single ginsenosides with anti-cancer potency have been isolated from the plant. Nevertheless, the specific cytotoxic effect of ginsenosides on cancer cells but not on normal cells has not yet been identified.

In the current studies, Compound **9**, a novel derivative from ginsenoside 20(*R*)-Rh2 with structure modification, exhibited specific cytotoxic effect to a panel of cancer cells but not to the normal human lung fibroblasts *in vitro*. At the same time, it could significantly suppress tumor growth in LLC-1 xenograft-bearing mice, but without significant negative impairments to the general condition and immune organs of the animals. *In vitro* studies showed that Compound **9** treatment induced a significant cell cycle arrest in S phase concomitant with down-regulation of Cdks and Cyclins alongside up-regulation of p21 and p27 expression. And, the complex formation between Cdk2/Cyclin E and Cdk4/Cyclin D1 were decreased, while the recruitments of p21 or p27 to Cyclin E/Cdk2 complex increased. In addition, the

Compound 9-induced cell death and S phase arrest could be significantly attenuated by knockdown of p21 or p27 protein. Compound 9 could also activate MAPK and p53 pathways, leading to subsequent activation of p27/p21 and suppression of Cyclin/Cdk complex activity. However, only the inhibitor of ERK (U0126) could suppress Compound 9-induced cytotoxicity and up-regulation of p53/p27 or /p21 and egr-1/p27 or /p21 expression.

The F-box protein s-phase kinase-associated protein 2 (skp2), which acts as an oncogene through targeting p27 for degradation, is overexpressed in many different human cancers. With treatment of Compound 9, the skp2 autoinduction loop was shut off via blocking the expression of skp2 and then resulted in inhibition of p27 degradation, activation of Cyclin E/Cdk 2, phosphorylation of Rb, and E2F release. And, the Compound 9-induced cytotoxicity and S phase cell cycle arrest in cancer cells could be attenuated by over-expression of skp2 gene, indicating an important role being paid by skp2 in Compound 9-mediated *in vitro* tumor suppression.

DNA damage occurs in all phases of a cell cycle of cancer cells, especially when the cells pass through S phase during which DNA get synthesized. In our experiments, Compound 9 treatment could induce activation of ATM and increase phosphorylation of Chk1/Cdc25C/H2A.X, which eventually resulted in lack of the activated Cyclin B1/Cdk1 and thereafter led to unable movement of the cells through the mitotic phase.

Moreover, Compound 9 could significantly and dose-dependently inhibit the invasive ability of cancer cells *in vitro*, while this anti-invasive action could be partially associated with suppression of VEGF, COX-2 and MMP-9 which are usually

over-expressed in tumor cells.

In conclusion, a novel anti-cancer derivative of ginsenoside 20(*R*)-Rh2 has been at the first time identified in current studies, which showed effectively in suppression of tumor growth in LLC-1 bearing mice but without significant negative impairment to the general condition and immune organs of the animals. Mechanistic studies on the anti-cancer effect of Compound **9** showed closely association with induction of S phase arrest of the cancer cell cycle via up-regulation of p21 and p27, suppression of Cyclin/Cdk complex activity and VEGF, COX-2 and MMP-9 expression. Interestingly, Compound **9** had no cytotoxic effect to the normal human lung fibroblasts. Taken together, Compound **9** has potentials as a novel candidate anti-cancer agent for further investigation.

TABLES OF CONTENTS

DECLARATION	i
ABSTRACT	ii
ACKNOWLEDGEMENTS	v
TABLES OF CONTENTS	vii
LIST OF FIGURES	xiii
LIST OF TABLES	xv
LIST OF ABBREVIATIONS	xvi
Chapter 1 Pathogenesis of Cancer and Commonly-used Anti-cancer Drugs	1
1.1 Pathogenesis and Diagnosis of Cancers	1
1.1.1 Definition	1
1.1.2 Classification.....	2
1.1.3 Etiologic Factors for Cancer	3
1.1.3.1 Lifestyle	4
1.1.3.2 Infection	4
1.1.3.3 Radiation.....	5
1.1.3.4 Environmental Carcinogens.....	6
1.1.3.5 Heredity.....	7
1.1.4 The Major Molecular Mechanisms Related to Pathogenesis of Cancers	7
1.1.4.1 Apoptosis.....	7
1.1.4.2. Caspase Cascade and Apoptosome Assembly	10
1.1.4.3 Key Molecules to Cancer Biology	10
1.1.5 Diagnosis.....	13
1.1.6 Treatment of Cancer.....	14
1.1.6.1 Surgery	14
1.1.6.2 Chemotherapy	15
1.1.6.3 Radiotherapy/Radiation Therapy	15
1.1.6.4 Complementary and Alternative Medicine	16
1.2 The Commonly-used Anti-cancer Drugs	16
1.2.1 Classification Based on Chemical Structures and Resource of Drugs .	17
1.2.1.1 Alkylating Agents	17
1.2.1.2 Anti-metabolites.....	19
1.2.1.3 Antibiotics	21
1.2.1.4 Plant Extracts	22
1.2.1.5 Platinum Compounds.....	23
1.2.1.6 Hormones	24
1.2.2 Classification Based on Biochemical Mechanisms of Anti-cancer	
Action.....	24

1.2.2.1 Inhibition on the Synthesis of Pre-DNA Molecule Building Blocks	25
1.2.2.2 Directly Damaging DNA in the Nucleus of Cancer Cells	26
1.2.2.3 Affecting Synthesis or Breakdown of the Mitotic Spindles.....	26
1.2.3 Classification Based on the Cell Cycle or Phase Specificity of Drugs.	26
Chapter 2 Advancement in Ginseng Research and General Design of the Current Investigation	28
2.1 Advancement in Ginseng Research	28
2.1.1 General Introduction	28
2.1.2 Chemical Components and Biological Activities	29
2.1.2.1 The Major Chemical Components	29
2.1.2.2. Deglycosylation of Ginsenosides by Intestinal Bacteria	32
2.1.3 Clinical Application of Ginseng for Treatment of Cancer	32
2.1.4 Pharmacological Activities of Ginseng Related to Cancer	34
2.1.4.1 Mechanistic Studies on Anti-cancer.....	34
2.1.4.2 Possible Application of Ginseng or its Ingredients for Cancer Treatment as Supplementary Therapy	40
2.1.5 Studies on the Toxicity of Ginseng.....	45
2.2 Aims and General Design of the Current Investigation.....	46
Chapter 3 Screening for the <i>in Vitro</i> Anti-cancer Fractions from Ginseng Extracts and Ginsenosides and Analysis on the Anti-cancer Activity-structure Relationship of the PPD-type Ginsenoside Derivatives.....	49
3.1 Introduction	49
3.2 Materials and Methods	51
3.2.1 Instruments and Materials.....	51
3.2.2 Preparation of the Hydrolysates of EAG and Ginsenoside Fractions...	52
3.2.3 HPLC Analysis of Ginsenosides in EAGH, PPTH and PPDH.....	52
3.2.4 Synthesis of Derivatives of PPD.....	53
3.2.5 Cancer Cell Lines and Cell Culture	54
3.2.6 Assay of the Cytotoxic Activity in Cancer Cells	55
3.3 Statistical analyses	56
3.4 Results	57
3.4.1 Cytotoxicity of EAGH in LLC-1 Cells.....	57
3.4.2 Cytotoxicity of PPDH and PPTH	60
3.4.3 Cytotoxic Potencies of the PPD-type Ginsenosides and Structurally-modified PPD-type Derivatives.....	67
3.5 Discussions	72

3.6 Conclusions	75
Chapter 4 Anti-cancer Effect of Compound 9 <i>in Vitro</i> and <i>in Vivo</i>	76
4.1 Introduction	76
4.2 Materials and Methods	79
4.2.1 Cell Culture and Cytotoxicity Assay	79
4.2.2 Animals	80
4.2.3 Xenograft Models and Treatment Protocol.....	80
4.3 Statistical Analyses	81
4.4 Results	82
4.4.1 Specific Suppression of Cancer Cell Growth <i>in Vitro</i> by Compound 9	82
4.4.2 Significant Suppressive Effect of Compound 9 on the Xenograft Lung Tumor Growth in mice by Intraperitoneal Injection.....	84
4.5 Discussions	90
4.6 Conclusions	93
Chapter 5 Effect of Compound 9 on Cell Cycle Regulation and Involvement of the MAPK Pathways.....	94
5.1 Introduction	94
5.2 Materials and Methods	96
5.2.1 Reagents.....	96
5.2.2 Cell Culture and Cytotoxic Assay.....	97
5.2.3 Analysis of Cell Cycle Distribution	97
5.2.4 Protein Extraction and Western Blotting	98
5.2.5 Immunoprecipitation (IP) -immunoblotting Assay.....	98
5.2.5.1 Preparation of Lysates.....	98
5.2.5.2 Pre-clearing the Lysates	99
5.2.5.3 Immunoprecipitation.....	99
5.2.6 RNA Interference	99
5.2.7 Cell Culture with MAPK Inhibitors.....	100
5.3 Statistical Analyses	100
5.4 Results	101
5.4.1 Morphological Changes Induced by Treatment of Compound 9 in LLC-1 Cancer Cells.....	101
5.4.2 Compound 9 Induced S Phase Cell Cycle Arrest in LLC-1 Cells	102

5.4.3 Compound 9 Reduced the Protein Level of S Phase Specific Cdk/Cyclins	104
5.4.4 Compound 9 Increases Protein Levels of the Cell Cycle Regulatory Molecules	106
5.4.5 Compound 9 Influences Interactions among Cell Cycle Regulators in LLC-1 Cancer Cells	108
5.4.6 p21 and p27 Knockdown Reduces Compound 9-induced Cell Cycle Arrest in LLC-1 Cancer Cells	111
5.4.7 Effect of Compound 9 on MAPK Signaling Pathway	113
4.7.1 Compound 9 Increased <i>phospho</i> -p38, <i>phospho</i> -JNK, and <i>phospho</i> -ERK Protein Expressions	113
4.7.2 Compound 9-mediated Cell Death Involved Modification of MAPKs and p53 Signaling Pathways	114
5.5 Discussions	117
5.6 Conclusions	120
Chapter 6 Involvement of <i>skp2</i> Autoinduction Loop and PI3K/Akt Signaling Pathway in the Compound 9-mediated S Phase Arrest and Cell Death	121
6.1 Introduction	121
6.2 Materials and Methods	124
6.2.1 Reagents	124
6.2.2 Protein Extraction and Western Blotting	124
6.2.3 Cell Culture with <i>Skp2</i> Plasmid Transient Transfection	124
6.2.4 Assay of Cytotoxicity	125
6.2.5 Analysis of Cell Cycle Distribution	125
6.3 Statistical Analyses	125
6.4 Results	126
6.4.1 Effect of Compound 9 on <i>Skp2</i> Autoinduction Loop	126
6.4.2 Role of <i>Skp2</i> in the Cytotoxic Effect of Compound 9	128
6.4.3 Role of <i>Skp2</i> in the Compound 9-induced S Phase Arrest	129
6.4.4 Effect of Compound 9 on PI3K/Akt Signaling Pathway	130
6.5 Discussions	132
6.6 Conclusions	135
Chapter 7 Role of DNA Damage in the Compound 9-induced S Phase Arrest and Cell Death	136
7.1 Introduction	136

7.2 Materials and Methods	138
7.2.1 Reagents	138
7.2.2 DNA Synthesis Assay	138
7.2.3 Protein Extraction and Western Blotting	139
7.2.4 Cell Culture with ATM/ATR Inhibitor	140
7.3 Statistical Analyses	140
7.4 Results	141
7.4.1 Compound 9 Suppresses DNA Synthesis in Dose-dependent Manner	141
7.4.2 Compound 9 Induced Ser139 Phosphorylation of H2A.X in Tumor Cells but not in Normal Cells.....	142
7.4.3 Effect of Compound 9 on the ATM/ATR-Chk1/2-Cdc25C Signaling Pathway.....	144
7.4.4 Compound 9-mediated Cell Death and Cell Cycle Arrest Induced by Modification of ATM/ATR Signaling Pathway	146
7.5 Discussions	148
7.6 Conclusions	151
Chapter 8 Effect of Compound 9 on the Invasive Ability of Lung Cancer Cells	152
8.1 Introduction	152
8.2 Materials and Methods	155
8.2.1 Reagents.....	155
8.2.2 Assay of Cell Invasion Ability	155
8.2.3 Protein Extraction and Western Blotting	156
8.3 Statistical Analyses	156
8.4 Results	157
8.4.1 Compound 9 Decreased the Invasion Ability of H1299 Cells.....	157
8.4.2 Compound 9 Down-regulated ICAM-1, VEGF, MMP-9, and COX-2 Expression.....	159
8.5 Discussions	160
8.6 Conclusions	163
Chapter 9 Summary and Future Work	164
9.1 Summary of the Current Research	164

9.1.1 Compound 9 Was Selected for Its Specific-cytotoxicity After Screening from PPD-type Ginsenoside Derivatives	164
9.1.2 Significant Antitumor Effect of Compound 9 both <i>In Vitro</i> and <i>In Vivo</i>	166
9.1.3 Compound 9-mediated S Phase Arrest Is Caused by p21- and p27-dependent Inhibition on Cyclins/Cdks via ERK Signaling Pathway ...	166
9.1.4 Compound 9-induced S Phase Arrest Is Partly Caused by Shutting Off Skp2 Autoinduction Loop Involving PI3K/Akt Signaling Pathway.....	167
9.1.5 Compound 9-caused S Phase Arrest Is Modulated by DNA Damage Through ATM/Chk1/Cdc25C-dependent Signaling Pathway.....	168
9.1.6 Compound 9 Significantly and Dose-dependently Inhibit the Invasive Ability	169
9.2 Future Works	170
REFERENCES.....	172
PUBLICATIONS	192
CURRICULUM VITAE	194